Xilio Therapeutics, Inc. (XLO)
NASDAQ: XLO · Real-Time Price · USD
8.62
+0.09 (1.06%)
Mar 26, 2026, 9:24 AM EDT - Market open
Xilio Therapeutics Revenue
In the year 2025, Xilio Therapeutics had annual revenue of $43.77M with 589.88% growth. Xilio Therapeutics had revenue of $13.69M in the quarter ending December 31, 2025, with 693.85% growth.
Revenue (ttm)
$43.77M
Revenue Growth
+589.88%
P/S Ratio
1.13
Revenue / Employee
$683,844
Employees
64
Market Cap
49.85M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 43.77M | 37.42M | 589.88% |
| Dec 31, 2024 | 6.34M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Metagenomi Therapeutics | 25.21M |
| Radiopharm Theranostics | 10.86M |
| Nutriband | 2.28M |
| Rallybio | 858.00K |
| Lisata Therapeutics | 170.00K |
XLO News
- 3 days ago - Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 8 days ago - Xilio Therapeutics to Present New Preclinical Data for its Masked T Cell Engager Program Targeting CLDN18.2 at the American Association for Cancer Research (AACR) Annual Meeting - GlobeNewsWire
- 14 days ago - Xilio Therapeutics Announces 1-for-14 Reverse Stock Split - GlobeNewsWire
- 24 days ago - Xilio Therapeutics to Present at the Leerink Partners Global Healthcare Conference - GlobeNewsWire
- 24 days ago - Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 weeks ago - Xilio Therapeutics Announces Pricing of Underwritten Offering - GlobeNewsWire
- 2 months ago - Xilio Therapeutics Highlights Upcoming Milestones and Recent Corporate Updates - GlobeNewsWire
- 4 months ago - Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial Results - GlobeNewsWire